Nivestim (Filgrastim)

Filgrastim, the active ingredient in Nivestim, is a granulocyte colony‑stimulating factor presented as a sterile injectable solution for subcutaneous or intravenous use. It is used to increase neutrophil counts in patients with chemotherapy‑induced neutropenia, after bone‑marrow transplantation, in aplastic anemia, and to mobilize peripheral blood stem cells.

GNH USA supplies Nivestim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Nivestim is a granulocyte colony‑stimulating factor indicated for several hematologic conditions: - Chemotherapy‑induced neutropenia: helps restore neutrophil counts and reduce infection risk. - Post‑bone‑marrow transplantation neutropenia: supports rapid neutrophil recovery. - Aplastic anemia: stimulates production of neutrophil precursors. - Peripheral blood stem cell mobilization: enhances collection of stem cells for transplantation.

Filgrastim may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bone pain: discomfort in the limbs or back. - Injection site reactions: redness, swelling, or itching. - Fever or chills: transient temperature elevation. - Nausea or vomiting: mild gastrointestinal upset. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and shock. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Allergic reactions: rash, urticaria, or anaphylaxis. - Leukocytosis: excessively high white‑blood‑cell count. - Capillary leak syndrome: edema and low blood pressure.

Before using Nivestim, consider the following safety measures: - Assess baseline neutrophil count: ensure appropriate indication before administration. - Monitor for splenic enlargement: perform periodic imaging in high‑risk patients. - Evaluate for hypersensitivity: discontinue if severe allergic reaction occurs. - Adjust dose in renal impairment: follow prescriber guidance for patients with reduced kidney function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim may interact with other agents that affect blood cell production or immune function.

Major Interactions (Avoid): - Chemotherapy agents that cause profound myelosuppression: may blunt the intended neutrophil response. - Corticosteroids at high doses: can reduce the efficacy of neutrophil stimulation.

Moderate Interactions (Monitor Closely): - Antimicrobial agents (e.g., antibiotics, antifungals): monitor for overlapping toxicities. - Immunosuppressants (e.g., cyclosporine, tacrolimus): watch for altered immune response. - Other growth factors (e.g., erythropoietin): assess cumulative hematologic effects.